核酸疗法CDMO市场－全球产业规模、份额、趋势、机会和预测，按类型、服务、应用、地区和竞争格局划分，2020-2030年预测

2024年全球核酸疗法CDMO市场规模为115.2亿美元，预计2030年将以8.29%的复合年增长率成长至185.8亿美元。核酸疗法是一类独特的药物，利用DNA或RNA等遗传物质来调节基因表达，以达到治疗目的，涵盖反义寡核苷酸、小干扰RNA和信使RNA等多种疗法。全球核酸疗法合约开发与生产组织（CDMO）市场的主要驱动力是生物製药研发投入的增加、新型核酸药物候选产品管线的不断扩充以及对专业生产能力的迫切需求。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球核酸疗法CDMO市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依类型（基因疗法、RNA疗法）
  • 依服务类型（製程开发与最佳化、製造服务、分析与品质控制服务、其他）
  • 依应用领域（肿瘤学、遗传性疾病、传染病、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美核酸疗法CDMO市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲核酸疗法CDMO市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区核酸疗法CDMO市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东与非洲核酸疗法CDMO市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲核酸疗法CDMO市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球核酸治疗药物CDMO市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Catalent Inc.
• Thermo Fisher Scientific Inc.
• Lonza Group Ltd.
• FUJIFILM Diosynth Biotechnologies USA, Inc.
• Charles River Laboratories International, Inc.
• Eurofins Genomics
• Sirion Biotech GmbH
• Oxford Biomedica Plc.
• Danaher Corp.

第十六章：策略建议

第17章调查会社について・免责事项

The Global Nucleic Acid Therapeutics CDMO Market, valued at USD 11.52 Billion in 2024, is projected to experience a CAGR of 8.29% to reach USD 18.58 Billion by 2030. Nucleic acid therapeutics represent a distinct class of pharmaceutical products utilizing genetic material, such as DNA or RNA, to modulate gene expression for therapeutic purposes, encompassing modalities like antisense oligonucleotides, small interfering RNAs, and messenger RNAs. The global Contract Development and Manufacturing Organization (CDMO) market for these therapeutics is primarily driven by expanding biopharmaceutical research and development investments, the increasing pipeline of novel nucleic acid drug candidates, and the critical need for specialized manufacturing capabilities.

Key Market Drivers

The expanding therapeutic pipeline for nucleic acid modalities significantly underpins the growth of the Contract Development and Manufacturing Organization market. The increasing number of novel drug candidates, including antisense oligonucleotides, messenger RNAs, and small interfering RNAs, necessitates specialized expertise and infrastructure for their development and large-scale production. These modalities offer targeted approaches for previously intractable diseases, creating a robust demand for outsourced services. For example, according to the article "Advancements in clinical RNA therapeutics: Present developments and prospective outlooks" published in PMC in April 2024, the exploration of antisense oligonucleotide-based therapies alone has progressed through 100 Phase I trials, with 25% of these advancing to Phase II or III trials, indicating a substantial volume of candidates requiring further development and manufacturing support. This progression through clinical stages directly translates into a requirement for advanced process development, analytical testing, and Good Manufacturing Practice compliant production.

Key Market Challenges

The inherent complexity and scalability issues associated with manufacturing advanced nucleic acid therapeutics, particularly in consistently achieving required quality and purity standards at commercial production volumes, represent a significant impedance to the growth of the global Contract Development and Manufacturing Organization (CDMO) market. These modalities often require specialized equipment, highly controlled environments, and intricate purification processes, leading to elevated operational costs and extended development timelines for CDMOs. Such manufacturing intricacies limit the capacity of CDMOs to efficiently process the increasing pipeline of novel drug candidates, creating bottlenecks within the supply chain.

Key Market Trends

Strategic Capacity Expansion Initiatives represent a significant trend as Contract Development and Manufacturing Organizations invest heavily to meet the escalating demand for nucleic acid therapeutics. This involves constructing new facilities, expanding existing operational footprints, and integrating advanced equipment to enhance overall manufacturing throughput and capabilities. Such proactive investments are crucial for ensuring the reliable and timely supply of critical drug substances and products, thereby supporting the clinical and commercial progression of novel therapies. For instance, according to a BioSpace report in January 2024, Lonza projected flat sales for the year but confirmed mid-term guidance and reported full-year 2023 sales of $7.75 billion, driven by strong performance in its Biologics and Small Molecules divisions, highlighting sustained investment in its manufacturing network. In October 2024, Lonza also completed the acquisition of a large-scale biologics facility in Vacaville, US, from Roche, further expanding its capabilities and dedicating CHF 1.4 billion of CapEx in 2024 towards its organic investment program for future growth across technologies.

Key Market Players

• Catalent Inc.
• Thermo Fisher Scientific Inc.
• Lonza Group Ltd.
• FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
• Charles River Laboratories International, Inc.
• Eurofins Genomics
• Sirion Biotech GmbH
• Oxford Biomedica Plc.
• Danaher Corp.

Report Scope:

In this report, the Global Nucleic Acid Therapeutics CDMO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Nucleic Acid Therapeutics CDMO Market, By Type:

• Gene Therapy
• RNA-based Therapies

Nucleic Acid Therapeutics CDMO Market, By Service:

• Process Development & Optimization
• Manufacturing Services
• Analytical and Quality Control Services
• Others

Nucleic Acid Therapeutics CDMO Market, By Application:

• Oncology
• Genetic Disorders
• Infectious Diseases
• Others

Nucleic Acid Therapeutics CDMO Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Nucleic Acid Therapeutics CDMO Market.

Available Customizations:

Global Nucleic Acid Therapeutics CDMO Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Nucleic Acid Therapeutics CDMO Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Gene Therapy, RNA-based Therapies)
  • 5.2.2. By Service (Process Development & Optimization, Manufacturing Services, Analytical and Quality Control Services, Others)
  • 5.2.3. By Application (Oncology, Genetic Disorders, Infectious Diseases, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Nucleic Acid Therapeutics CDMO Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Service
  • 6.2.3. By Application
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Nucleic Acid Therapeutics CDMO Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Service
      • 6.3.1.2.3. By Application
  • 6.3.2. Canada Nucleic Acid Therapeutics CDMO Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Service
      • 6.3.2.2.3. By Application
  • 6.3.3. Mexico Nucleic Acid Therapeutics CDMO Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Service
      • 6.3.3.2.3. By Application

7. Europe Nucleic Acid Therapeutics CDMO Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Service
  • 7.2.3. By Application
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Nucleic Acid Therapeutics CDMO Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Service
      • 7.3.1.2.3. By Application
  • 7.3.2. France Nucleic Acid Therapeutics CDMO Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Service
      • 7.3.2.2.3. By Application
  • 7.3.3. United Kingdom Nucleic Acid Therapeutics CDMO Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Service
      • 7.3.3.2.3. By Application
  • 7.3.4. Italy Nucleic Acid Therapeutics CDMO Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Service
      • 7.3.4.2.3. By Application
  • 7.3.5. Spain Nucleic Acid Therapeutics CDMO Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Service
      • 7.3.5.2.3. By Application

8. Asia Pacific Nucleic Acid Therapeutics CDMO Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Service
  • 8.2.3. By Application
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Nucleic Acid Therapeutics CDMO Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Service
      • 8.3.1.2.3. By Application
  • 8.3.2. India Nucleic Acid Therapeutics CDMO Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Service
      • 8.3.2.2.3. By Application
  • 8.3.3. Japan Nucleic Acid Therapeutics CDMO Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Service
      • 8.3.3.2.3. By Application
  • 8.3.4. South Korea Nucleic Acid Therapeutics CDMO Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Service
      • 8.3.4.2.3. By Application
  • 8.3.5. Australia Nucleic Acid Therapeutics CDMO Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Service
      • 8.3.5.2.3. By Application

9. Middle East & Africa Nucleic Acid Therapeutics CDMO Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Service
  • 9.2.3. By Application
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Nucleic Acid Therapeutics CDMO Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Service
      • 9.3.1.2.3. By Application
  • 9.3.2. UAE Nucleic Acid Therapeutics CDMO Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Service
      • 9.3.2.2.3. By Application
  • 9.3.3. South Africa Nucleic Acid Therapeutics CDMO Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Service
      • 9.3.3.2.3. By Application

10. South America Nucleic Acid Therapeutics CDMO Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Service
  • 10.2.3. By Application
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Nucleic Acid Therapeutics CDMO Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Service
      • 10.3.1.2.3. By Application
  • 10.3.2. Colombia Nucleic Acid Therapeutics CDMO Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Service
      • 10.3.2.2.3. By Application
  • 10.3.3. Argentina Nucleic Acid Therapeutics CDMO Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Service
      • 10.3.3.2.3. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Nucleic Acid Therapeutics CDMO Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Catalent Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Thermo Fisher Scientific Inc.
• 15.3. Lonza Group Ltd.
• 15.4. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
• 15.5. Charles River Laboratories International, Inc.
• 15.6. Eurofins Genomics
• 15.7. Sirion Biotech GmbH
• 15.8. Oxford Biomedica Plc.
• 15.9. Danaher Corp.

16. Strategic Recommendations

17. About Us & Disclaimer